Valley Brook Capital Group Inc. Sells 1,035 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Valley Brook Capital Group Inc. has reduced its position in Thermo Fisher Scientific Inc. by 23.5%, selling 1,035 shares and now holding a total of 3,375 shares valued at approximately $1.68 million.
• During the same period, other institutional investors have shown varied activity, with Mondrian Investment Partners LTD increasing its holdings by 146.1% to own 214,506 shares worth over $106 million.
• Thermo Fisher recently reported earnings of $5.36 per share, exceeding estimates, with a revenue increase of 2.9% year-over-year, along with announcing a quarterly dividend of $0.43 per share to be paid on October 15th.

Valley Brook Capital Group Inc. decreased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 23.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,375 shares of the medical research company's stock after selling 1,035 shares during the period. Thermo Fisher Scientific makes up 1.3% of Valley Brook Capital Group Inc.'s investment portfolio, making the stock its 22nd largest holding. Valley Brook Capital Group Inc.'s holdings in Thermo Fisher Scientific were worth $1,679,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also bought and sold shares of the company. Bernard Wealth Management Corp. purchased a new stake in Thermo Fisher Scientific in the fourth quarter worth $25,000. Ameriflex Group Inc. purchased a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth about $30,000. IMA Advisory Services Inc. purchased a new position in Thermo Fisher Scientific during the 1st quarter valued at about $35,000. Navigoe LLC purchased a new stake in Thermo Fisher Scientific in the fourth quarter worth about $37,000. Finally, Smallwood Wealth Investment Management LLC bought a new position in shares of Thermo Fisher Scientific during the first quarter valued at approximately $37,000. 89.23% of the stock is owned by institutional investors.

Analyst Ratings Changes

TMO has been the subject of a number of analyst reports. Barclays raised their price objective on Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a research report on Thursday, July 24th. Royal Bank Of Canada reduced their price target on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Wells Fargo & Company dropped their price target on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research note on Thursday, July 24th. Evercore ISI reduced their price target on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Finally, Stifel Nicolaus cut their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. Sixteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $593.00.

Insider Activity

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $451.82, for a total transaction of $4,518,200.00. Following the completion of the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $52,037,916.68. This represents a 7.99% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders sold 18,896 shares of company stock worth $8,593,838 in the last ninety days. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO traded up $16.88 during midday trading on Friday, hitting $500.64. 787,452 shares of the company's stock traded hands, compared to its average volume of 2,477,885. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The stock has a market capitalization of $189.05 billion, a price-to-earnings ratio of 28.98, a price-to-earnings-growth ratio of 2.64 and a beta of 0.74. The firm has a fifty day moving average of $441.06 and a 200 day moving average of $458.02. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same period last year, the firm earned $5.37 earnings per share. The company's quarterly revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio is presently 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.